Neuromodulation – the future of diabetes treatments

Abstract

have diabetes in the UK alone, and approximately 90% of these individuals have type 2 diabetes mellitus (T2DM). Patients with type 2 diabetes lose normal control of blood sugar levels, resulting in an overload of sugar in the blood, known as poor blood implementation of interventions such as medication, surgery, and dietary changes. For example, approximately 50% of type 2 diabetics do not take medications as prescribed. This is often due to the unwanted side effects of diabetic medications. Even the treatment options – GLP-1 receptor agonists – which improve glycaemic control are linked to kidney injury and severe nausea. Adherence to GLP-1 receptor agonist therapy is also a continuing problem, even with once-weekly injections. The urgent need for better and more effective treatments is an ongoing challenge in the research industry.